MSD states “Keytruda is an innovative antibody that will create its own pipeline itself”
The pharmaceutical industry has paid attention on the domestically first anti-PD-1 immunotherapy ‘Keytruda’.
On the 14th, MSD Korea announced that it held a press conference to introduce the role and clinical benefit of an immunotherapy as a new antibody paradigm and the research result of clini...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
